WVU Rockefeller Neuroscience Institute continues its mission to advance treatment of brain aneurysms with its participation in the clinical trial of a new device called SEAL. SEAL stands for Saccular ...

WVU Rockefeller Neuroscience Institute continues its mission to advance treatment of brain aneurysms with its participation ...

WVU Rockefeller Neuroscience Institute are in next phases of their groundbreaking aneurysm device trial. The Seal-It trials ...

Allarity Therapeutics is advancing the clinical development of stenoparib toward FDA approval, indicating progress in their drug development pipeline. The new Phase 2 clinical trial protocol ...

Though it was seven phone generations ago, overstuffing 2017's Galaxy Note 7 infamously led their batteries to catch fire. Samsung could pitch the S25 Edge's thinner size to consumers looking for ...

RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that Cohort 3 of its Phase 1 clinical trial enrolled three patients and all ...

Indaptus Therapeutics, Inc. has received Clinical Trial Authorization from Health Canada to expand its U.S. clinical trial of Decoy20, a treatment for cancer and viral infections, into Canadian sites.

In other recent news, Alterity Therapeutics has announced several key developments. The company has completed a Phase 2 clinical trial, marking a significant step in its drug development programs.

Let's take a look at what these Wall Street heavyweights have to say about Viking Therapeutics, Inc. (VKTX) before we discuss the reliability of brokerage recommendations and how to use them to your ...

Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today announced the ...